$0.90
1.67% today
Nasdaq, Sep 16, 08:21 pm CET
ISIN
US23283X2062
Symbol
CTSO

CytoSorbents Corporation Target price 2025 - Analyst rating & recommendation

CytoSorbents Corporation Classifications & Recommendation:

Buy
75%
Hold
25%

CytoSorbents Corporation Price Target

Target Price $4.08
Price $0.92
Potential
Number of Estimates 5
5 Analysts have issued a price target CytoSorbents Corporation 2026 . The average CytoSorbents Corporation target price is $4.08. This is higher than the current stock price. The highest price target is
$10.50 1,047.16%
register free of charge
, the lowest is .
A rating was issued by 8 analysts: 6 Analysts recommend CytoSorbents Corporation to buy, 2 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the CytoSorbents Corporation stock has an average upside potential 2026 of . Most analysts recommend the CytoSorbents Corporation stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 35.59 39.84
14.47% 11.94%
EBITDA Margin -41.33% -30.80%
56.92% 25.48%
Net Margin -58.22% -20.84%
38.12% 64.20%

5 Analysts have issued a sales forecast CytoSorbents Corporation 2025 . The average CytoSorbents Corporation sales estimate is

$39.8m
Unlock
. This is
16.29% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$41.8m 22.08%
Unlock
, the lowest is
$37.0m 8.13%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $35.6m 14.47%
2025
$39.8m 11.94%
Unlock
2026
$48.3m 21.22%
Unlock
2027
$62.8m 30.10%
Unlock
2028
$88.6m 40.94%
Unlock
2029
$133m 50.23%
Unlock
2030
$277m 108.56%
Unlock
2031
$343m 23.74%
Unlock
2032
$453m 31.88%
Unlock

3 Analysts have issued an CytoSorbents Corporation EBITDA forecast 2025. The average CytoSorbents Corporation EBITDA estimate is

$-12.3m
Unlock
. This is
13.28% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-12.6m 10.73%
Unlock
, the lowest is
$-11.8m 16.68%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-14.7m 50.69%
2025
$-12.3m 16.58%
Unlock
2026
$-3.4m 72.59%
Unlock

EBITDA Margin

2024 -41.33% 56.92%
2025
-30.80% 25.48%
Unlock
2026
-6.96% 77.40%
Unlock

5 CytoSorbents Corporation Analysts have issued a net profit forecast 2025. The average CytoSorbents Corporation net profit estimate is

$-8.3m
Unlock
. This is
14.87% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-4.6m 52.82%
Unlock
, the lowest is
$-11.7m 19.59%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-20.7m 29.16%
2025
$-8.3m 59.94%
Unlock
2026
$-5.5m 33.37%
Unlock
2027
$2.2m 140.51%
Unlock

Net Margin

2024 -58.22% 38.12%
2025
-20.84% 64.20%
Unlock
2026
-11.46% 45.01%
Unlock
2027
3.56% 131.06%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -0.38 -0.13
41.54% 65.79%
P/E negative
EV/Sales 1.55

5 Analysts have issued a CytoSorbents Corporation forecast for earnings per share. The average CytoSorbents Corporation EPS is

$-0.13
Unlock
. This is
7.14% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-0.07 50.00%
Unlock
, the lowest is
$-0.19 35.71%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-0.38 41.54%
2025
$-0.13 65.79%
Unlock
2026
$-0.09 30.77%
Unlock
2027
$0.04 144.44%
Unlock

P/E ratio

Current -6.54 184.52%
2025
-6.90 5.54%
Unlock
2026
-10.35 50.00%
Unlock
2027
25.64 347.73%
Unlock

Based on analysts' sales estimates for 2025, the CytoSorbents Corporation stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 1.80 4.65%
2025
1.55 14.07%
Unlock
2026
1.28 17.51%
Unlock
2027
0.98 23.14%
Unlock
2028
0.70 29.05%
Unlock
2029
0.46 33.43%
Unlock
2030
0.22 52.05%
Unlock
2031
0.18 19.18%
Unlock
2032
0.14 24.18%
Unlock

P/S ratio

Current 1.68 6.00%
2025
1.44 14.00%
Unlock
2026
1.19 17.51%
Unlock
2027
0.91 23.14%
Unlock
2028
0.65 29.05%
Unlock
2029
0.43 33.44%
Unlock
2030
0.21 52.06%
Unlock
2031
0.17 19.18%
Unlock
2032
0.13 24.15%
Unlock

Current CytoSorbents Corporation Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
D. Boral Capital
Locked
Locked
Locked Aug 20 2025
D. Boral Capital
Locked
Locked
Locked Aug 08 2025
D. Boral Capital
Locked
Locked
Locked Jul 21 2025
D. Boral Capital
Locked
Locked
Locked Jun 25 2025
HC Wainwright & Co.
Locked
Locked
Locked May 15 2025
D. Boral Capital
Locked
Locked
Locked May 15 2025
D. Boral Capital
Locked
Locked
Locked May 02 2025
Analyst Rating Date
Locked
D. Boral Capital:
Locked
Locked
Aug 20 2025
Locked
D. Boral Capital:
Locked
Locked
Aug 08 2025
Locked
D. Boral Capital:
Locked
Locked
Jul 21 2025
Locked
D. Boral Capital:
Locked
Locked
Jun 25 2025
Locked
HC Wainwright & Co.:
Locked
Locked
May 15 2025
Locked
D. Boral Capital:
Locked
Locked
May 15 2025
Locked
D. Boral Capital:
Locked
Locked
May 02 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today